CEO Blaser buys 10,540 shares of QDEL at $23.59; stock down 45.0% from 52-week high; cluster buy pattern detected.
CEO Brian J. Blaser purchased 10,540 shares at $23.59, increasing his holdings by 35.7% to 40,073 shares. The transaction occurs at a significant discount to the 52-week high of $42.89 (currently down 45.0%) and notably in a cluster pattern with 2 other insiders buying within the past 14 days. However, the company is unprofitable with net income of $-733.0M against revenue of $699.9M, and annual revenue contracted 7.2% year-over-year. Blaser's own cross-ticker track record shows a 0.00% 90-day win rate on prior buys, and his previous purchase at QDEL on 2024-12-11 returned -10.0% over 90 days, suggesting his timing at this ticker has not historically been favorable. The convergence of multiple insider purchases amid fundamental deterioration and depressed valuation warrants investor attention.
CEO Blaser bought 23.5K QDEL shares at $21.34, tripling stake to 29.5K amid -7.2% revenue decline, -$733.0M annual loss
Brian J. Blaser, President and CEO, purchased 23,500 shares at $21.34, increasing his total holdings by 389.5% from 6,033 to 29,533 shares. This acquisition occurs at a critical juncture for QuidelOrtho: the company reported -$733.0M net income over its most recent full fiscal year with annual revenue declining 7.2%, and the stock is currently -55.2% from its 52-week high. Blaser's prior buy at this ticker in December 2024 produced a 90-day return of -10.0%, establishing a pattern of purchases that has not delivered positive medium-term returns. The timing and magnitude of this buy—occurring as the stock has fallen 28.6% in 30 days and the company remains unprofitable—suggests the insider views current valuations as an opportunity, though his historical execution at QDEL provides no evidence of successful entry point selection.
CEO Brian Blaser purchases 6,033 shares of QDEL at $41.42 amid company's first full-year loss and -8.2% revenue decline
President and CEO Brian Blaser purchased 6,033 shares at $41.42 on 2024-12-11, establishing a position following a prior zero holding. The transaction occurs in a deteriorated financial environment: the company reported a negative net income of -$19.9M over its most recent full fiscal year and annual revenue contracted -8.2% year-over-year, with the latest quarter generating $727.1M in revenue. The stock is currently priced at $41.35, down -45.2% from its 52-week high of $75.44, and has declined -9.1% over the past 90 days despite a +3.3% 30-day rebound. A top executive's new purchase in a loss-making, declining-revenue environment warrants investor attention to understand the company's operational trajectory and management's forward outlook.
